Fig. 3From: Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemiaa OS in 41 AML patients with complete consolidation therapy classify by cytogenetic risk. b OS in 41 AML patients with complete consolidation therapy with HiDAC and IDAC regimen. c RFS in 41 AML patients with complete consolidation therapy classify by cytogenetic risk. d RFS in 41 AML patients with complete consolidation therapy with HiDAC and IDAC regimenBack to article page